175 related articles for article (PubMed ID: 37731205)
21. Mobilan: a recombinant adenovirus carrying Toll-like receptor 5 self-activating cassette for cancer immunotherapy.
Mett V; Komarova EA; Greene K; Bespalov I; Brackett C; Gillard B; Gleiberman AS; Toshkov IA; Aygün-Sunar S; Johnson C; Karasik E; Bapardekar-Nair M; Kurnasov OV; Osterman AL; Stanhope-Baker PS; Morrison C; Moser MT; Foster BA; Gudkov AV
Oncogene; 2018 Jan; 37(4):439-449. PubMed ID: 28967901
[TBL] [Abstract][Full Text] [Related]
22. Cytotoxicity of CD19-CAR-NK92 cells is primarily mediated via perforin/granzyme pathway.
Althaus J; Nilius-Eliliwi V; Maghnouj A; Döring S; Schroers R; Hudecek M; Hahn SA; Mika T
Cancer Immunol Immunother; 2023 Aug; 72(8):2573-2583. PubMed ID: 37052701
[TBL] [Abstract][Full Text] [Related]
23. Recombinant TLR5 agonist CBLB502 promotes NK cell-mediated anti-CMV immunity in mice.
Hossain MS; Ramachandiran S; Gewirtz AT; Waller EK
PLoS One; 2014; 9(5):e96165. PubMed ID: 24879439
[TBL] [Abstract][Full Text] [Related]
24. [Valproate up-regulates the expression of NKG2DL through the MEK/ERK signaling pathway to enhance the killing effect of NK cells on A375 human melanoma cells].
Li S; Wang Y; Yan H
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2022 Jan; 38(1):32-38. PubMed ID: 35078573
[TBL] [Abstract][Full Text] [Related]
25. Chimeric Antigen Receptor-modified T Cells Repressed Solid Tumors and Their Relapse in an Established Patient-derived Colon Carcinoma Xenograft Model.
Teng R; Zhao J; Zhao Y; Gao J; Li H; Zhou S; Wang Y; Sun Q; Lin Z; Yang W; Yin M; Wen J; Deng H
J Immunother; 2019; 42(2):33-42. PubMed ID: 30586347
[TBL] [Abstract][Full Text] [Related]
26. Inducible localized delivery of an anti-PD-1 scFv enhances anti-tumor activity of ROR1 CAR-T cells in TNBC.
Harrasser M; Gohil SH; Lau H; Della Peruta M; Muczynski V; Patel D; Miranda E; Grigoriadis K; Grigoriadis A; Granger D; Evans R; Nathwani AC
Breast Cancer Res; 2022 Jun; 24(1):39. PubMed ID: 35659040
[TBL] [Abstract][Full Text] [Related]
27. A chimeric switch-receptor PD1-DAP10-41BB augments NK92-cell activation and killing for human lung Cancer H1299 Cell.
Zhi L; Yin M; Su X; Zhang Z; Lu H; Li M; Guo C; Niu Z; Zhang X; Zhu W
Biochem Biophys Res Commun; 2022 Apr; 600():94-100. PubMed ID: 35217362
[TBL] [Abstract][Full Text] [Related]
28. A modifiable universal cotinine-chimeric antigen system of NK cells with multiple targets.
Kang HY; Lee SY; Kim HM; Lee SU; Lee H; Cho MY; Oh SC; Kim SM; Park HS; Han EH; Kim SE; Kim H; Yoon SR; Doh J; Chung J; Hong KS; Choi I; Kim TD
Front Immunol; 2022; 13():1089369. PubMed ID: 36713381
[TBL] [Abstract][Full Text] [Related]
29. A TLR5 agonist inhibits acute renal ischemic failure.
Fukuzawa N; Petro M; Baldwin WM; Gudkov AV; Fairchild RL
J Immunol; 2011 Oct; 187(7):3831-9. PubMed ID: 21890657
[TBL] [Abstract][Full Text] [Related]
30. Tethering IL2 to Its Receptor IL2Rβ Enhances Antitumor Activity and Expansion of Natural Killer NK92 Cells.
Jounaidi Y; Cotten JF; Miller KW; Forman SA
Cancer Res; 2017 Nov; 77(21):5938-5951. PubMed ID: 28916655
[TBL] [Abstract][Full Text] [Related]
31. Novaferon gene modification promotes NK92 cell anti-tumor activity.
Zhang W; Yu B; Meng Q; Pu L; Liu B; Li F
Int Immunopharmacol; 2023 Sep; 122():110613. PubMed ID: 37421776
[TBL] [Abstract][Full Text] [Related]
32. Combination Therapy with EpCAM-CAR-NK-92 Cells and Regorafenib against Human Colorectal Cancer Models.
Zhang Q; Zhang H; Ding J; Liu H; Li H; Li H; Lu M; Miao Y; Li L; Zheng J
J Immunol Res; 2018; 2018():4263520. PubMed ID: 30410941
[TBL] [Abstract][Full Text] [Related]
33. Pan-HDAC inhibitors augment IL2-induced proliferation of NK cells via the JAK2-STAT5B signaling pathway.
Zheng J; Lu Y; Xiao J; Duan Y; Zong S; Chen X; Hu T; Li L; Zhang Y
Int Immunopharmacol; 2023 Mar; 116():109753. PubMed ID: 36738675
[TBL] [Abstract][Full Text] [Related]
34. CBLB502, a Toll-like receptor 5 agonist, offers protection against radiation-induced male reproductive system damage in mice.
Bai H; Sun F; Yang G; Wang L; Zhang Q; Zhang Q; Zhan Y; Chen J; Yu M; Li C; Yin R; Yang X; Ge C
Biol Reprod; 2019 Jan; 100(1):281-291. PubMed ID: 30084935
[TBL] [Abstract][Full Text] [Related]
35. HER2-specific chimeric antigen receptor-T cells for targeted therapy of metastatic colorectal cancer.
Xu J; Meng Q; Sun H; Zhang X; Yun J; Li B; Wu S; Li X; Yang H; Zhu H; Aschner M; Relucenti M; Familiari G; Chen R
Cell Death Dis; 2021 Nov; 12(12):1109. PubMed ID: 34839348
[TBL] [Abstract][Full Text] [Related]
36. Anti-PSMA CAR-engineered NK-92 Cells: An Off-the-shelf Cell Therapy for Prostate Cancer.
Montagner IM; Penna A; Fracasso G; Carpanese D; Dalla Pietà A; Barbieri V; Zuccolotto G; Rosato A
Cells; 2020 Jun; 9(6):. PubMed ID: 32498368
[TBL] [Abstract][Full Text] [Related]
37. HCT-116 colorectal cancer cells secrete chemokines which induce chemoattraction and intracellular calcium mobilization in NK92 cells.
Elemam NM; Al-Jaderi Z; Hachim MY; Maghazachi AA
Cancer Immunol Immunother; 2019 Jun; 68(6):883-895. PubMed ID: 30847498
[TBL] [Abstract][Full Text] [Related]
38. Chimeric antigen receptor T cells engineered to recognize the P329G-mutated Fc part of effector-silenced tumor antigen-targeting human IgG1 antibodies enable modular targeting of solid tumors.
Stock S; Benmebarek MR; Kluever AK; Darowski D; Jost C; Stubenrauch KG; Benz J; Freimoser-Grundschober A; Moessner E; Umana P; Subklewe M; Endres S; Klein C; Kobold S
J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35902133
[TBL] [Abstract][Full Text] [Related]
39. Two-step enhanced cancer immunotherapy with engineered
Zheng JH; Nguyen VH; Jiang SN; Park SH; Tan W; Hong SH; Shin MG; Chung IJ; Hong Y; Bom HS; Choy HE; Lee SE; Rhee JH; Min JJ
Sci Transl Med; 2017 Feb; 9(376):. PubMed ID: 28179508
[TBL] [Abstract][Full Text] [Related]
40. Significantly increased anti-tumor activity of carcinoembryonic antigen-specific chimeric antigen receptor T cells in combination with recombinant human IL-12.
Chi X; Yang P; Zhang E; Gu J; Xu H; Li M; Gao X; Li X; Zhang Y; Xu H; Hu J
Cancer Med; 2019 Aug; 8(10):4753-4765. PubMed ID: 31237116
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]